Cardiovascular effects of sulphonylureas: role of K(ATP) channels.
Howes
L G
LG
Department of Clinical Pharmacology, St George Hospital, Kogarah, Australia. l.howes@unsw.edu.au
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology; D002319:Cardiovascular System / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology*; D013453:Sulfonylurea Compounds / Q000494:pharmacology* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D015221:Potassium Channels; D013453:Sulfonylurea Compounds; D000255:Adenosine Triphosphate